It’s the intention of the Medical Informatics Funding Scheme and different nationwide and native tasks for digital networking in healthcare to facilitate the trade and use of affected person knowledge between establishments in compliance with knowledge safety laws.
This requires the mixing of information from varied sources-such as digital office methods, laboratory methods, image archiving and communication (PAC) methods or tumor boards-into a knowledge warehouse or analysis databases. Digital networking of service suppliers and analysis establishments will open entry to high-performance and precision medication (e.g., digital molecular tumor boards) for much more sufferers, thereby offering knowledge for primary and care analysis.
Community medication will set up the translational hyperlink between primary analysis (e.g., genome analysis) and affected person care. Digitally built-in “actual world” affected person knowledge will even facilitate an in depth evaluation of well being care and the standard of therapies.
Robotics in Pediatric Urology: Evolution and the Future
Virtually 30 years have handed for the reason that inception of minimally invasive surgical procedure in urology and particularly in pediatric urology. Laparoscopy has now grow to be an important software within the pediatric urologic armamentarium. The applying of robot-assisted surgical procedure in pediatrics has allowed for widespread utilization for widespread reconstructive procedures similar to pyeloplasty and ureteral reimplantation.
Understanding the implementation, technical concerns, and outcomes are crucial for continued success and adoption. This has allowed for elevated use in additional complicated urologic procedures similar to redo pyeloplasty, dismembered ureteral reimplantation, catheterizable channel creation, and bladder augmentation.
The Significance of Reporting Scientific and Epidemiological Knowledge in Urology: Native Experiences and Insights from the Worldwide Literature
Pathologies of the genito-urinary tract are chargeable for a substantial illness burden worldwide, resulting in vital losses of earnings, misplaced working days, elevated expenditures for nationwide healthcare methods, and decreased high quality of life (QoL) within the affected sufferers. Amongst these ailments, infections and malignancies on this anatomical area are a few of the most necessary sicknesses in human medication; however, benign prostate hyperplasia (BPH), erectile dysfunction, hypospadias, urinary incontinence, and vesicoureteral reflux are additionally related issues affecting hundreds of thousands.
The publication of assorted microbiological and medical research in urology from totally different geographical areas has necessary ramifications from the standpoint of epidemiology: on one hand, reported knowledge might affect the event of therapeutic tips for urinary tract infections (UTIs) (empiric antibiotic-therapy) and malignancies (together with classical cytotoxic drug protocols and next-generation anticancer therapies) each regionally and internationally; alternatively, the related stakeholders and authorities representatives usually base their choices on printed proof.
Due to this fact, novel research within the subject of urology are strongly inspired to keep up and enhance the excessive commonplace of affected person care internationally and to make sure steady data provide for worldwide datasets on the causative brokers of UTIs and most cancers registries. The current Editorial goals to spotlight some related research printed from the sphere of urology in Medicina during the last a number of years.
Cannabinoids in urology. Which benign circumstances may they be acceptable to deal with: A scientific assessment
There’s rising proof suggesting cannabinoids might present appropriate alternate options to traditional therapies in an growing variety of medical settings. This assessment evaluates how cannabinoids are used to deal with sure benign urological pathologies and to make clear the medical worth of this knowledge.
This assessment consists of 62 papers and was undertaken per PRISMA’s tips, it evidences the therapeutic potential of cannabinoids within the administration of particular benign urological ailments, most notably neurogenic bladder dysfunction (medical research), renal illness (animal research) and interstitial cystitis (animal research). Nevertheless, while cannabinoids are more and more used, they can’t be thought-about dependable alternate options to extra recognised therapies.
Ckj consolidation amongst Q1 Urology and Nephrology journals
The Scientific Kidney Journal (ckj) affect issue from Clarivate’s Net of Science for 2019 was 3.388. This consolidates ckj amongst journals within the high 25% (first quartile, Q1) within the Urology and Nephrology subject based on the journal affect issue.
The manuscripts contributing probably the most to the affect issue targeted on power kidney illness (CKD) epidemiology and analysis, CKD problems and their administration, cost-efficiency of renal substitute remedy, pathogenesis of CKD, familial kidney illness and the environment-genetics interface, onconephrology, expertise, SGLT2 inhibitors and consequence prediction. We offer right here an summary of the most well liked and most impactful matters for 2017-19.
Black pearl in urology: Inadvertent anastomosis of gonadal vein to ureter resulting in malpostioning of stent into the inferior vena cava
Double- J (JJ) stents are generally utilized in urological procedures. Minor and self limiting problems are widespread following JJ stenting. Malpositioning of JJ stent into the vascular system is a uncommon and a probably deadly complication. We’re reporting a case of a malpositioned JJ stent within the inferior vena cava (IVC), throughout Boari flap process for post-hysterectomy uretereovaginal fistula.
Affected person had undergone hysterectomy three months beforehand, and had ureterovaginal fistula probably attributable to iatrogenic intraoperative damage. Affected person underwent right-sided ureteroneocystostomy with Boari flap one week beforehand at different institute. Affected person was admitted in our establishment with complaints of fever, ache in stomach and vomiting.
 anti-Galectin 1 |
|
YF-PA12945 |
Abfrontier |
100 ug |
EUR 403 |
|
Description: Rabbit polyclonal to Galectin 1 |
 Rabbit Polyclonal antibody Anti-CRBN |
|
Anti-CRBN |
ImmunoStep |
50 µg |
EUR 349 |
 Anti-Galectin 1 Antibody |
|
A00470-2 |
BosterBio |
100ug/vial |
EUR 294 |
 Anti-Galectin-1 antibody |
|
STJ98716 |
St John's Laboratory |
200 µl |
EUR 197 |
|
Description: Rabbit polyclonal to Galectin-1. |
Anti-Galectin-1 antibody |
|
STJ93201 |
St John's Laboratory |
200 µl |
EUR 197 |
|
Description: Rabbit polyclonal to Galectin-1. |
 anti- Galectin-1 antibody |
|
FNab03314 |
FN Test |
100µg |
EUR 505.25 |
|
|
|
Description: Antibody raised against Galectin-1 |
anti- Galectin-1 antibody |
|
FNab03315 |
FN Test |
100µg |
EUR 548.75 |
|
|
|
Description: Antibody raised against Galectin-1 |
) Anti-Galectin 1 (1A8) |
|
YF-MA13984 |
Abfrontier |
100 ug |
EUR 363 |
|
Description: Mouse monoclonal to Galectin 1 |
 Anti-Galectin 1/LGALS1 Antibody |
|
PA1422 |
BosterBio |
100ug/vial |
EUR 334 |
Anti-Galectin 1/LGALS1 Antibody |
|
PB9240 |
BosterBio |
100ug/vial |
EUR 334 |
 Anti-Galectin 1/Lgals1 Antibody |
|
A00470 |
BosterBio |
100ug/vial |
EUR 334 |
 Anti-Galectin 1 Biotinylated Antibody |
|
A00470-Biotin |
BosterBio |
50ug/vial |
EUR 294 |
) anti-Galectin 1 (1E8-1B2) |
|
LF-MA10174 |
Abfrontier |
100 ug |
EUR 363 |
|
Description: Mouse monoclonal to Galectin 1 |
 / Placental Protein 13 (PP13) Monoclonal Antibody) Anti-Galectin-13 (GAL13) / Placental Protein 13 (PP13) Monoclonal Antibody |
|
M08143-1 |
BosterBio |
100ug/vial |
EUR 397 |
|
Description: Mouse Monoclonal Galectin-13 (GAL13) / Placental Protein 13 (PP13) Antibody. Validated in IHC and tested in Human. |
 anti-Galectin 3 |
|
YF-PA12946 |
Abfrontier |
50 ug |
EUR 363 |
|
Description: Mouse polyclonal to Galectin 3 |
anti-Galectin 3 |
|
YF-PA12947 |
Abfrontier |
100 ul |
EUR 403 |
|
Description: Rabbit polyclonal to Galectin 3 |
anti-Galectin 3 |
|
YF-PA12948 |
Abfrontier |
100 ug |
EUR 403 |
|
Description: Rabbit polyclonal to Galectin 3 |
 anti-Galectin 8 |
|
YF-PA12951 |
Abfrontier |
50 ul |
EUR 363 |
|
Description: Mouse polyclonal to Galectin 8 |
anti-Galectin 3 |
|
YF-PA24079 |
Abfrontier |
50 ul |
EUR 334 |
|
Description: Mouse polyclonal to Galectin 3 |
 anti-galectin 9 |
|
YF-PA24081 |
Abfrontier |
50 ul |
EUR 334 |
|
Description: Mouse polyclonal to galectin 9 |
 anti-Galectin 13 |
|
YF-PA18585 |
Abfrontier |
50 ug |
EUR 363 |
|
Description: Mouse polyclonal to Galectin 13 |
 Polyclonal Goat anti-GST μ-form |
|
GST-ANTI-2 |
Detroit R&D |
50 uL |
EUR 280 |
 Polyclonal Goat anti-GST p-form |
|
GST-ANTI-3 |
Detroit R&D |
50 uL |
EUR 280 |
 Anti-human Galectin-3 antibody |
|
STJ15100163 |
St John's Laboratory |
250 µg |
EUR 336 |
|
Description: This monoclonal antibody is for studies of antigen expression in cells and tissue sections using immunocytochemistry and immunoprecipitation |
 LGALS7 Human, Galectin-7 Human Recombinant Protein, His Tag |
|
PROTP47929-1 |
BosterBio |
Regular: 20ug |
EUR 317 |
|
Description: Galectin-7 Human Recombinant fused with a 20 amino acid His tag at N-terminus produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 156 amino acids (1-136 a.a.) and having a molecular mass of 17.2kDa. ;The Galectin-7 is purified by proprietary chromatographic techniques. |
 LGALS3 Human, Galectin-3 Human Recombinant Protein, His Tag |
|
PROTP17931-1 |
BosterBio |
Regular: 25ug |
EUR 317 |
|
Description: LGALS3 Human Recombinant produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 270 amino acids (1-250 a.a.) and having a molecular mass of 28.3 kDa._x000D_ The LGALS3 is fused to a 20 amino acid His-Tag at N-terminus and purified by proprietary chromatographic techniques. _x000D_ |
 LGALS8 Human, Galectin-8 Human Recombinant Protein, His Tag |
|
PROTO00214-1 |
BosterBio |
Regular: 10ug |
EUR 317 |
|
Description: LGALS8 Human Recombinant produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 337 amino acids (1-317 a.a.) and having a molecular mass of 37.9 kDa. The LGALS8 is fused to a 20 amino acid His-Tag at N-terminus and purified by proprietary chromatographic techniques. |
 AssayMax ELISA Kit) Human Galectin-3 (Gal-3) AssayMax ELISA Kit |
|
EG3311-1 |
AssayPro |
96 Well Plate |
EUR 477 |
 AssayMax ELISA Kit) Human Galectin-4 (Gal-4) AssayMax ELISA Kit |
|
EG3312-1 |
AssayPro |
96 Well Plate |
EUR 477 |
) Human Galectin-1 (LGALS1) |
|
1-CSB-EP012882HU |
Cusabio |
-
EUR 380.00
-
EUR 214.00
-
EUR 1309.00
-
EUR 560.00
-
EUR 873.00
-
EUR 262.00
|
- 100ug
- 10ug
- 1MG
- 200ug
- 500ug
- 50ug
|
|
|
|
Description: Recombinant Human Galectin-1(LGALS1) expressed in E.coli |
Human Galectin-1 (LGALS1) |
|
1-CSB-EP012882HUb1 |
Cusabio |
-
EUR 380.00
-
EUR 214.00
-
EUR 1309.00
-
EUR 560.00
-
EUR 873.00
-
EUR 262.00
|
- 100ug
- 10ug
- 1MG
- 200ug
- 500ug
- 50ug
|
|
|
|
Description: Recombinant Human Galectin-1(LGALS1) expressed in E.coli |
 Human Galectin 1 Protein |
|
20-abx066725 |
Abbexa |
-
EUR 620.00
-
EUR 272.00
-
EUR 1859.00
-
EUR 732.00
-
EUR 453.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
|
 Recombinant Human Galectin-1 |
|
7-00427 |
CHI Scientific |
10µg |
Ask for price |
Recombinant Human Galectin-1 |
|
7-00428 |
CHI Scientific |
50µg |
Ask for price |
 Galectin-1, human recombinant |
|
4648-10 |
Biovision |
|
EUR 142 |
Galectin-1, human recombinant |
|
4648-1000 |
Biovision |
|
EUR 1648 |
Galectin-1, human recombinant |
|
4648-50 |
Biovision |
|
EUR 262 |
 Anti-Galectin 3 antibody |
|
STJ190057 |
St John's Laboratory |
200 µl |
EUR 197 |
|
Description: Unconjugated Mouse monoclonal to Galectin 3 (AS1A24) |
 Anti-Galectin-9 Antibody |
|
A03415 |
BosterBio |
100ul |
EUR 397 |
|
Description: Rabbit Polyclonal Antibody for Galectin-9 Antibody (LGALS9) detection.tested for WB in Human, Mouse, Rat. |
 Anti-Galectin-3 antibody |
|
STJ96945 |
St John's Laboratory |
200 µl |
EUR 197 |
|
Description: Galectin-3 is a protein encoded by the LGALS3 gene which is approximately 26,1 kDa. Galectin-3 is localised to the cytoplasm and nucleus. It is involved in NF-kappaB signalling, advanced glycosylation end product receptor signalling and cell adhesion. It is a galactose-specific lectin which binds IgE and may mediate the stimulation by CSPG4 of endothelial cells migration along with the alpha-3, beta-1 integrin. It is characterized by an N-terminal proline-rich tandem repeat domain and a single C-terminal carbohydrate recognition domain. Galectin-3 is expressed mainly in the colonic epithelium and is also abundantly expressed in activated macrophages. Mutations in the LGALS3 gene may result in follicular adenoma and thyroid cancer. STJ96945 was developed from clone 6G2 and was affinity-purified from mouse ascites by affinity-chromatography using specific immunogen. This antibody detects endogenous galectin-3 proteins. |
Anti-Galectin-3 antibody |
|
STJ97549 |
St John's Laboratory |
200 µl |
EUR 197 |
|
Description: Mouse monoclonal to Galectin-3 (6B8). |
Anti-Galectin-3 antibody |
|
STJ97550 |
St John's Laboratory |
200 µl |
EUR 197 |
|
Description: Mouse monoclonal to Galectin-3 (8D7). |
Anti-Galectin-3 antibody |
|
STJ97551 |
St John's Laboratory |
200 µl |
EUR 197 |
|
Description: Mouse monoclonal to Galectin-3 (5D9). |
Anti-Galectin-3 antibody |
|
STJ97601 |
St John's Laboratory |
200 µl |
EUR 197 |
|
Description: Mouse monoclonal to Galectin-3 (2F9). |
Anti-Galectin-3 antibody |
|
STJ97604 |
St John's Laboratory |
200 µl |
EUR 197 |
|
Description: Mouse monoclonal to Galectin-3 (16E6). |
Anti-Galectin-3 antibody |
|
STJ97605 |
St John's Laboratory |
200 µl |
EUR 197 |
|
Description: Mouse monoclonal to Galectin-3 (1H4). |
Anti-Galectin-3 antibody |
|
STJ97715 |
St John's Laboratory |
200 µl |
EUR 197 |
|
Description: Mouse monoclonal to Galectin-3. |
 Anti-Galectin-2 antibody |
|
STJ93202 |
St John's Laboratory |
200 µl |
EUR 197 |
|
Description: Rabbit polyclonal to Galectin-2. |
 Anti-Galectin-4 antibody |
|
STJ93203 |
St John's Laboratory |
200 µl |
EUR 197 |
|
Description: Rabbit polyclonal to Galectin-4. |
 Anti-Galectin-7 antibody |
|
STJ93204 |
St John's Laboratory |
200 µl |
EUR 197 |
|
Description: Rabbit polyclonal to Galectin-7. |
 Anti-Galectin-8 antibody |
|
STJ93205 |
St John's Laboratory |
200 µl |
EUR 197 |
|
Description: Rabbit polyclonal to Galectin-8. |
 Anti-Galectin-9 antibody |
|
STJ93206 |
St John's Laboratory |
200 µl |
EUR 197 |
|
Description: Rabbit polyclonal to Galectin-9. |
 anti- Galectin 2 antibody |
|
FNab03310 |
FN Test |
100µg |
EUR 585 |
|
|
|
Description: Antibody raised against Galectin 2 |
 anti- Galectin 4 antibody |
|
FNab03311 |
FN Test |
100µg |
EUR 505.25 |
|
|
|
Description: Antibody raised against Galectin 4 |
 anti- Galectin 8 antibody |
|
FNab03312 |
FN Test |
100µg |
EUR 505.25 |
|
|
|
Description: Antibody raised against Galectin 8 |
 anti- Galectin 9 antibody |
|
FNab03313 |
FN Test |
100µg |
EUR 505.25 |
|
|
|
Description: Antibody raised against Galectin 9 |
 anti- Galectin-3 antibody |
|
FNab03316 |
FN Test |
100µg |
EUR 505.25 |
|
|
|
Description: Antibody raised against Galectin-3 |
anti- Galectin-3 antibody |
|
FNab03317 |
FN Test |
100µg |
EUR 548.75 |
|
|
|
Description: Antibody raised against Galectin-3 |
 anti- Galectin-7 antibody |
|
FNab03318 |
FN Test |
100µg |
EUR 505.25 |
|
|
|
Description: Antibody raised against Galectin-7 |
) anti-Galectin-3 (6G2) |
|
LF-MA20336 |
Abfrontier |
100 ug |
EUR 354 |
|
Description: Mouse monoclonal to Galectin-3 |
) Anti-Galectin 8 (3E5) |
|
YF-MA13986 |
Abfrontier |
100 ug |
EUR 363 |
|
Description: Mouse monoclonal to Galectin 8 |
 Anti Human Galectin-3 Polyclonal Antibody |
|
KH040 |
Sceti |
|
EUR 649 |
|
Description: The Anti Human Galectin-3 Polyclonal Antibody is available in Europe and for worldwide shipping via Gentaur. |
 Monoclonal Antibody) Anti-Galectin-1 / Human Placental Lactogen (hPL) Monoclonal Antibody |
|
M00470 |
BosterBio |
100ug/vial |
EUR 397 |
|
Description: Mouse Monoclonal Galectin-1 / Human Placental Lactogen (hPL) Antibody. Validated in IHC and tested in Human. |
) Galectin-1 (LGAS1) |
|
PR27143 |
Neuromics |
50 ug |
EUR 318 |
 Galectin 1 Antibody |
|
49673-100ul |
SAB |
100ul |
EUR 333 |
Galectin 1 Antibody |
|
49673-50ul |
SAB |
50ul |
EUR 239 |
 Galectin-1 Protein |
|
20-abx261634 |
Abbexa |
-
EUR 3418.00
-
EUR 328.00
-
EUR 230.00
|
|
|
|
Galectin-1 Protein |
|
20-abx263505 |
Abbexa |
-
EUR 230.00
-
EUR 1790.00
-
EUR 328.00
|
|
|
|
 Galectin-1 Antibody |
|
3596-100 |
Biovision |
|
EUR 316 |
Galectin-1 Antibody |
|
3596-30T |
Biovision |
|
EUR 146 |
 Galectin 1 protein |
|
30R-1385 |
Fitzgerald |
100 ug |
EUR 224 |
|
Description: Purified recombinant Human Galectin 1 protein |
Galectin 1 protein |
|
30R-2371 |
Fitzgerald |
50 ug |
EUR 353 |
|
Description: Purified recombinant Human Galectin 1 protein |
Galectin 1 protein |
|
30R-AG003 |
Fitzgerald |
10 ug |
EUR 133 |
|
Description: Purified recombinant Human Galectin 1 protein |
 Galectin 1 antibody |
|
70R-11939 |
Fitzgerald |
100 ug |
EUR 403 |
|
Description: Rabbit polyclonal Galectin 1 antibody |
Galectin 1 antibody |
|
70R-13963 |
Fitzgerald |
100 ug |
EUR 322 |
|
Description: Affinity purified Rabbit polyclonal Galectin 1 antibody |
Galectin 1 antibody |
|
70R-49997 |
Fitzgerald |
100 ul |
EUR 244 |
|
Description: Purified Polyclonal Galectin 1 antibody |
In view of the signs of the affected person, cross-sectional imaging with computed tomography scan was completed which revealed an intraoperatively malpositioned JJ stent within the IVC, and nicely healed Boari flap was seen.
